ArticleJACC. Case reports2026
Performance-Enhancing Drug-Associated Myocarditis in a Young Athlete: From Cardiogenic Shock to Clearance.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCurrent guidelines on activity restriction in myocarditis carry significant implications for athletes. CASE SUMMARY: We present a case of fulminant myocarditis in a 21-year-old athlete after performance-enhancing drug use. He presented with chest pain and dyspnea with ST-segment elevations on electrocardiogram. Coronary angiography was normal, and cardiac magnetic resonance confirmed myocarditis. His course was complicated by cardiogenic shock requiring inotropic support but improved with diuresis and high-dose corticosteroids. A shared decision-making approach guided a stepwise return-to-exercise strategy based on symptoms, biomarkers, cardiac magnetic resonance, and exercise stress testing. The patient gradually resumed training and returned to unrestricted exercise 3 months after presentation. DISCUSSION: This case demonstrates the value of individualized, shared decision-making for management of myocarditis in athletes. TAKE-HOME MESSAGES: Individualized, guideline-informed return-to-exercise strategies help balance safety with athlete goals after myocarditis. Screening for performance-enhancing drug exposure is essential because these agents may represent an underrecognized contributor to myocarditis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.